Annexon, Inc.
NASDAQ:ANNXBiotechnology
-$0.04 today
- Market cap
- $576.73M
- Beta
- 1.18
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.01
Volume 2.98M
Average 2.56M
ANNX Sales of Investments
Cash received from selling or redeeming investments.
Annexon, Inc.NASDAQ: ANNX
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments declines year over year
Q1 FY2026 sales of investments of $33M fell 79.3% year over year, behind the -45.0% change in trailing-twelve-month sales of investments. Sequentially, it fell 14.3% from the prior quarter. Over 3 fiscal years it compounded at +31.2% a year.
Context
- Sales of investments increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -79.3% toward the trailing-twelve-month pace of -45.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 402.4M USD
- Year-over-year change
- +10.2%
- 4-year CAGR
- +30.4%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 402.4M | +10.2% |
| FY2024 | 2024-12-31 | 365.15M | +104.0% |
| FY2023 | 2023-12-31 | 178.98M | +0.5% |
| FY2022 | 2022-12-31 | 178.17M | +28.2% |
| FY2021 | 2021-12-31 | 139.02M | — |
Sales of Investments vs competitors
How ANNX compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -45.0% is the 5th highest of 7, against a peer median of -26.6%.
- Over three fiscal years its annual growth of +31.2% compares with a peer median of +6.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $555.15M USD | +110.1% | +46.4% | 7504.0% |
| LTM Jun 2026 | $385.46M USD | -16.6% | +11.7% | 367.2% | |
| LTM Mar 2026 | $322.1M USD | -33.7% | +1.3% | 138.6% | |
| LTM Mar 2026 | $275.9M USD | -45.0% | +31.2% | — | |
| LTM Mar 2026 | $79.8M USD | -19.5% | -20.6% | 953.7% | |
| LTM Mar 2026 | €38.23M EUR | -49.0% | -17.3% | 130343.0% | |
| LTM Dec 2025 | CHF 16.05M CHF | — | — | 449.1% | |
| FY2025 | €480.27K EUR | — | +30.1% | — | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding ANNX) | — | -26.6% | +6.5% | 367.2% | |
Competitors are the stored peer set for ANNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (130.32M) | (141.95M) | (134.24M) | (138.2M) | (206.69M) |
| Depreciation & Amortization | 3.41M | 2.11M | 2.15M | 2.15M | 2.17M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 18.52M | 18.18M | 19.43M | 16.42M |
| Change in Working Capital | 3.28M | 3.74M | (5.81M) | 6.36M | 4.23M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.86M | (287K) | (2.08M) | 4.94M | 4.49M |
| Other Working Capital | (575K) | 4.03M | (3.73M) | 1.43M | (261K) |
| Other Non-Cash Items | 17.52M | 1.28M | (1.43M) | (7.75M) | (2.49M) |
| Operating Cash Flow | (106.11M) | (116.31M) | (121.14M) | (118.01M) | (186.36M) |
| Capital Expenditures | (1.65M) | (6.53M) | (193K) | (15K) | (137K) |
| Acquisitions (Net) | 0 | (64.97K) | 0 | 0 | 0 |
| Purchases of Investments | (225.6M) | (113.2M) | (108.09M) | (583.93M) | (212.21M) |
| Sales of Investments | 139.02M | 178.17M | 178.98M | 365.15M | 402.4M |
| Other Investing Activities | 0 | 64.97K | 0 | 0 | 0 |
| Investing Cash Flow | (88.24M) | 58.44M | 70.7M | (218.8M) | 190.05M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.8M | 130.48M | 135.51M | 161.87M | 110.47M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | (1.86M) |
| Other Financing Activities | 0 | (7.57M) | 14K | (665K) | 238K |
| Financing Cash Flow | 1.8M | 122.91M | 135.52M | 161.21M | 108.86M |
| Effect of Forex Changes | (1.17M) | 1K | 5K | (15K) | 2K |
| Net Change in Cash | (193.72M) | 65.04M | 85.09M | (175.61M) | 112.55M |
| Free Cash Flow | (107.76M) | (122.84M) | (121.34M) | (118.02M) | (186.49M) |
Annexon, Inc.
NASDAQ:ANNX
Intrinsic Alpha fair value
Locked
Current Price
$3.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.